The award ceremony in Brussels formed part of the first European Biotech Week, launched to celebrate the 60th anniversary of the discovery of the DNA molecular structure.
The five SMEs shortlisted for the award, which includes a €10,000 prize and two years’ membership of EuropaBio, included two UK firms.
PsiOxus is a clinical-stage biotech company that is developing novel cancer therapies, using directed evolution to develop a virus that targets and kills cancer cells with minimal harm to healthy cells.
Dr John Beadle, CEO of PsiOxus, said: “It is a great honour for PsiOxus to receive this award in recognition not only of the progress and the innovation generated by our own company but also in the UK bioscience industry in general.
“Our products and programs seek to treat cancer in highly innovative ways and this is only truly possible in an environment that is highly supportive of investment in innovative bioscience enterprises.”
“It’s great to see an innovative British company win this prestigious European award,” commented Steve Bates, CEO of the BioIndustry Association (BIA). “It confirms the UK’s position as the leading biotech cluster in the region.”
The EuropaBio Most Innovative EU Biotech SME Award highlights European biotech SMEs that have developed innovative solutions to technical, social and environmental problems.
EuropaBio, the European Association for Bioindustries, was formed in 1996 to represent the biotech industry in Europe.